Reduction of cerebrospinal fluid amyloid β after systemic administration of M1 muscarinic agonists

被引：63

作者：

Beach, TG

Walker, DG

Potter, PE

Sue, LI

Fisher, A

机构：

[1] Sun Hlth Res Inst, Sun City, AZ 85372 USA

[2] Midwestern Univ, Glendale, AZ USA

[3] Israel Inst Biol Res, IL-74100 Ness Ziona, Israel

来源：

BRAIN RESEARCH | 2001年 / 905卷 / 1-2期

基金：

美国国家卫生研究院;

关键词：

Alzheimer's disease; cholinergic; therapy; amyloid beta; muscarinic agonists; cerebrospinal fluid;

D O I：

10.1016/S0006-8993(01)02484-2

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Overproduction of the peptide amyloid beta (A beta) is a critical event in Alzheimer's disease (AD). Systemic administration of 3 Mi-selective muscarinic agonists, AF102B, AF150S and AF267B, decreased cerebrospinal fluid (CSF) A beta concentrations; levels of CSF secreted beta -APP were not significantly altered. Rabbits treated for 5 days with s.c. injections of each drug (2 mg/kg/day) had levels of CSF A beta which were between 55 and 71% of control for A beta 1-40 and between 59 and 84% of control for A beta 1-42. (C) 2001 Elsevier Science B.V. All rights reserved.

引用

页码：220 / 223

页数：4

共 23 条

[1] Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease
Andreasen, N
Hesse, C
Davidsson, P
Minthon, L
Wallin, A
Winblad, B
Vanderstichele, H
Vanmechelen, E
Blennow, K
[J]. ARCHIVES OF NEUROLOGY, 1999, 56 (06) : 673 - 680
[2] Increased beta-amyloid precursor protein mRNA in the rat cerebral cortex and hippocampus after chronic systemic atropine treatment
Beach, TG
Walker, DG
Cynader, MS
Hughes, LH
[J]. NEUROSCIENCE LETTERS, 1996, 210 (01) : 13 - 16
[3] ECKOLS K, 1995, LIFE SCI, V12, P83
[4] FARBER SA, 1995, J NEUROSCI, V15, P7442
[5] Fisher A, 2000, DRUG DEVELOP RES, V50, P291, DOI 10.1002/1098-2299(200007/08)50:3/4<291::AID-DDR12>3.0.CO
[6] 2-6
[7] Fisher A, 1997, Expert Opin Investig Drugs, V6, P1395, DOI 10.1517/13543784.6.10.1395
[8] Muscarinic receptor agonists in Alzheimer's disease - More than just symptomatic treatment?
Fisher, A
[J]. CNS DRUGS, 1999, 12 (03) : 197 - 214
[9] Haring R, 1998, J NEUROCHEM, V71, P2094
[10] Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions
Haroutunian, V
Greig, N
Pei, XF
Utsuki, T
Gluck, R
Acevedo, LD
Davis, KL
Wallace, WC
[J]. MOLECULAR BRAIN RESEARCH, 1997, 46 (1-2): : 161 - 168

← 1 2 3 →